Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Julie E RaabDepartment of Immunology and Microbiology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-6181-0830
Tucker B HarjuDepartment of Immunology and Microbiology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Jody D ToperzerDepartment of Immunology and Microbiology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Jeffrey K Duncan-LoweyDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Connon I ThomasDepartment of Cell and Developmental Biology, University of Colorado-Anschutz Medical Campus, , Aurora, Colorado, USA.
Anza DarehshouriDepartment of Cell and Developmental Biology, University of Colorado-Anschutz Medical Campus, , Aurora, Colorado, USA.
Marcia B GoldbergDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-4266-9733
Brian C RussoDepartment of Immunology and Microbiology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-6433-5617
Funding
Molecular signaling in Shigella disseminationR01AI081724 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 2010 to 2026
$7.1M
Molecular Pathogenesis of Infectious DiseasesT32AI052066 · NIAID · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2002 to 2022
$2.3M
The Role of Intermediate Filaments in InflammationR35GM146923 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Brian Russo · 2022 to 2026
$2.2M
The Type 3 Secretion System Translocon Pore in Bacterial PathogenesisK22AI137296 · NIAID · UNIVERSITY OF COLORADO DENVER · PI RUSSO, BRIAN · 2020 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A translocation-competent pore is required for · full record | OpenQuestion